Lipid profile at baseline, lipid-lowering treatment and treatment goal attainment, in sensitivity analyses restricted to adults with FH diagnosis and baseline total cholesterol ≥7.5 mmo/L (n=1805 at baseline)
| Baseline | 12 months | 24 months | ||
| Total cholesterol (mmol/L) | Mean (SD) | 8.62 (1.09) | 5.87 (1.47) | 5.68 (1.33) |
| LDL-cholesterol (mmol/L) | Mean (SD) | 6.16 (1.25) | 3.71 (1.45) | 3.51 (1.29) |
| HDL-cholesterol (mmol/L) | Mean (SD) | 1.53 (0.49) | 1.52 (0.48) | 1.53 (0.46) |
| Triglycerides (mmol/L) | Median (IQR) | 1.80 (1.29–2.65) | 1.40 (1.00–2.10) | 1.39 (1.00–2.00) |
| Potency of prescribed statins* | N (%) | (n=1805) | (n=1299) | (n=1172) |
| Low | 144 (7.98) | 84 (6.47) | 56 (4.78) | |
| Medium | 1231 (68.20) | 668 (51.42) | 572 (48.81) | |
| High | 430 (23.82) | 547 (42.11) | 544 (46.42) | |
| LDL-C reduction at time of follow-up | N (%) | (n=1805) | (n=982) | |
| Attained 50% reduction | 649 (35.96) | 423 (43.08) | ||
| Non-attained 50% reduction | 1156 (64.04) | 559 (56.92) |
*Statin potency at 12 months and 24 months was reported in individuals with records of LDL-C at 12 months, as well as records of statin potency at 12 and 24 months, respectively.
FH, familial hypercholesterolaemia; HDL, high-density lipoprotein; LDL, low-density lipoprotein.